Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.